Relief as Apex Indian court seeks details on trial safeguards
This article was originally published in Scrip
Executive Summary
In what perhaps will come as a significant relief for industry, the Supreme Court order in a case concerning clinical trials in India appears less harsh than originally made out to be, with the apex court only seeking certain details on how the current regime safeguards trial participants with reference to the clearances granted for 162 proposals by the Drugs Controller General of India (DCGI).